These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 35839046)
1. PD-1, PD-L1, NY-ESO-1, and MAGE-A4 expression in cutaneous angiosarcoma: A case report. Hashimoto K; Nishimura S; Shinyashiki Y; Ito T; Tanaka H; Ohtani K; Kakinoki R; Akagi M Medicine (Baltimore); 2022 Jul; 101(28):e29621. PubMed ID: 35839046 [TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression and clinicopathological assessment of PD-1, PD-L1, NY-ESO-1, and MAGE-A4 expression in highly aggressive soft tissue sarcomas. Hashimoto K; Nishimura S; Ito T; Kakinoki R; Akagi M Eur J Histochem; 2022 Apr; 66(2):. PubMed ID: 35448937 [TBL] [Abstract][Full Text] [Related]
3. The programmed cell death protein-1/programmed cell death ligand 1 expression, CD3+ T cell infiltration, NY-ESO-1 expression, and microsatellite instability phenotype in primary cutaneous melanoma and mucosal melanoma and their clinical significance and prognostic value: a study of 89 consecutive cases. Ren Y; Lv Q; Yue W; Liu B; Zou Z Melanoma Res; 2020 Feb; 30(1):85-101. PubMed ID: 31095042 [TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma. Chen K; Cheng G; Zhang F; Zhang N; Li D; Jin J; Wu J; Ying L; Mao W; Su D Oncotarget; 2016 May; 7(21):30772-80. PubMed ID: 27120796 [TBL] [Abstract][Full Text] [Related]
5. Soluble PD-L1 Concentration Is Proportional to the Expression of PD-L1 in Tissue and Is Associated with a Poor Prognosis in Esophageal Squamous Cell Carcinoma. Shiraishi T; Toyozumi T; Sakata H; Murakami K; Kano M; Matsumoto Y; Yokoyama M; Okada K; Kamata T; Ryuzaki T; Kinoshita K; Hirasawa S; Matsubara H Oncology; 2022; 100(1):39-47. PubMed ID: 34991094 [TBL] [Abstract][Full Text] [Related]
6. Programmed cell death-ligand 1 expression predicts poor treatment response and prognostic value in esophageal squamous cell carcinoma patients without esophagectomy. Zhang F; Zhu X; Zhang Q; Zhou P; Hao L Aging (Albany NY); 2021 Jul; 13(14):18827-18838. PubMed ID: 34297698 [TBL] [Abstract][Full Text] [Related]
7. Regulation of programmed cell death ligand 1 expression by atypical protein kinase C lambda/iota in cutaneous angiosarcoma. Kawamura A; Kawamura T; Riddell M; Hikita T; Yanagi T; Umemura H; Nakayama M Cancer Sci; 2019 May; 110(5):1780-1789. PubMed ID: 30801864 [TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population. Rong L; Liu Y; Hui Z; Zhao Z; Zhang Y; Wang B; Yuan Y; Li W; Guo L; Ying J; Song Y; Wang L; Zhou Z; Xue L; Lu N Diagn Pathol; 2019 Jan; 14(1):6. PubMed ID: 30684971 [TBL] [Abstract][Full Text] [Related]
9. Epigenetic modulation combined with PD-1/PD-L1 blockade enhances immunotherapy based on MAGE-A11 antigen-specific CD8+T cells against esophageal carcinoma. Wu Y; Sang M; Liu F; Zhang J; Li W; Li Z; Gu L; Zheng Y; Li J; Shan B Carcinogenesis; 2020 Jul; 41(7):894-903. PubMed ID: 32529260 [TBL] [Abstract][Full Text] [Related]
10. Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma. Faiena I; Astrow SH; Elashoff DA; Jain R; Bot A; Chamie K; Belldegrun AS; Pantuck AJ; Drakaki A Cancer Immunol Immunother; 2019 May; 68(5):743-751. PubMed ID: 30790015 [TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma. Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915 [TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma. Guo W; Zhang F; Shao F; Wang P; Li Z; Yang X; He Z; Shi S; Gao Y; He J Hum Pathol; 2019 Feb; 84():291-298. PubMed ID: 30296523 [TBL] [Abstract][Full Text] [Related]
13. Tumor microenvironment and its clinicopathological and prognostic associations in surgically resected cutaneous angiosarcoma. Bi Y; Ge L; Ren X; Pang J; Zhao Y; Liang Z Clin Transl Oncol; 2022 May; 24(5):941-949. PubMed ID: 35064455 [TBL] [Abstract][Full Text] [Related]
14. Refractory solitary cervical lymph node metastasis after esophageal squamous cell carcinoma surgery and its successful treatment with immune checkpoint inhibitor: A case report and literature review. Song W; Wang H; Tian Y; Liu S; Chen X; Cui J; Zhao Y Medicine (Baltimore); 2020 Mar; 99(10):e19440. PubMed ID: 32150096 [TBL] [Abstract][Full Text] [Related]
15. Antiprogrammed cell death protein 1 immunotherapy for angiosarcoma with high programmed death-ligand 1 expression: a case report. Xu F; Zheng J; Fu M; Zhou H Immunotherapy; 2020 Aug; 12(11):771-776. PubMed ID: 32611263 [No Abstract] [Full Text] [Related]
16. The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma. Akutsu Y; Murakami K; Kano M; Toyozumi T; Matsumoto Y; Takahashi M; Otsuka R; Sekino N; Yokoyama M; Shiraishi T; Matsubara H Esophagus; 2018 Apr; 15(2):103-108. PubMed ID: 29892935 [TBL] [Abstract][Full Text] [Related]
17. MAGE-A is More Highly Expressed Than NY-ESO-1 in a Systematic Immunohistochemical Analysis of 3668 Cases. Kerkar SP; Wang ZF; Lasota J; Park T; Patel K; Groh E; Rosenberg SA; Miettinen MM J Immunother; 2016 May; 39(4):181-7. PubMed ID: 27070449 [TBL] [Abstract][Full Text] [Related]
18. Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma. Kim R; Keam B; Kwon D; Ock CY; Kim M; Kim TM; Kim HJ; Jeon YK; Park IK; Kang CH; Kim DW; Kim YT; Heo DS World J Gastroenterol; 2016 Oct; 22(37):8389-8397. PubMed ID: 27729745 [TBL] [Abstract][Full Text] [Related]
19. Involvement of NY-ESO-1 and MAGE-A4 in the pathogenesis of desmoid tumors. Hashimoto K; Nishimura S; Shinyashiki Y; Ito T; Kakinoki R; Akagi M Medicine (Baltimore); 2023 Jun; 102(22):e33908. PubMed ID: 37266606 [TBL] [Abstract][Full Text] [Related]
20. PD-L1 and PD-L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma. Okadome K; Baba Y; Yasuda-Yoshihara N; Nomoto D; Yagi T; Toihata T; Ogawa K; Sawayama H; Ishimoto T; Iwatsuki M; Iwagami S; Miyamoto Y; Yoshida N; Watanabe M; Komohara Y; Baba H Cancer Sci; 2022 Feb; 113(2):399-410. PubMed ID: 34773342 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]